Northwest Biotherapeutics Overview
- Year Founded
-
1996
- Status
-
Public
- Employees
-
25
- Stock Symbol
-
NWBO
- Investments
-
2
- Share Price
-
$0.28
- (As of Friday Closing)
Northwest Biotherapeutics General Information
Description
Northwest Biotherapeutics Inc is a biotechnology company involved in the development of cancer vaccines. The target is a broad range of solid-tumor cancers. The company has a proprietary manufacturing technology, which it uses to produce a personalized vaccine. The product portfolio includes product candidates such as DCVax-L, for patients with brain cancer; DCVax-Direct, direct injection into all types of inoperable solid tumor cancers, and DCVax for late-stage ovarian cancer. DCVax-Prostate, for late-stage prostate cancer, has received clearance from the U.S Food and Drug Administration.
Contact Information
Website
www.nwbio.comCorporate Office
- 4800 Montgomery Lane
- Suite 800
- Bethesda, MD 20814
- United States
Corporate Office
- 4800 Montgomery Lane
- Suite 800
- Bethesda, MD 20814
- United States
Northwest Biotherapeutics Stock Performance
As of 13-Jun-2025, Northwest Biotherapeutics’s stock price is $0.28. Its current market cap is $400M with 1.44B shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.28 | $0.26 | $0.17 - $0.50 | $400M | 1.44B | 3.85M | -$0.07 |
Northwest Biotherapeutics Financials Summary
As of 31-Mar-2025, Northwest Biotherapeutics has a trailing 12-month revenue of $1.47M.
|
In Thousands, USD |
TTM 31-Mar-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 398,420 | 433,391 | 867,856 | 860,860 |
| Revenue | 1,473 | 1,382 | 1,932 | 1,683 |
| EBITDA | (74,921) | (73,967) | (55,625) | (97,464) |
| Net Income | (84,809) | (83,778) | (62,599) | (105,032) |
| Total Assets | 27,505 | 26,728 | 27,865 | 31,323 |
| Total Debt | 69,005 | 67,440 | 45,560 | 26,253 |
Northwest Biotherapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Northwest Biotherapeutics Comparisons
Industry
Financing
Details
Northwest Biotherapeutics Competitors (55)
One of Northwest Biotherapeutics’s 55 competitors is Aura Biosciences, a Formerly VC-backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Aura Biosciences | Formerly VC-backed | Cambridge, MA | ||||
| Apellis Pharmaceuticals | Formerly VC-backed | Waltham, MA | ||||
| Oncorus | Formerly VC-backed | Andover, MA | ||||
| Advanced Proteome Therapeutics | Corporation | Boston, MA | ||||
| Sagimet Biosciences | Formerly VC-backed | San Mateo, CA |
Northwest Biotherapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Northwest Biotherapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Northwest Biotherapeutics Acquisitions (2)
Northwest Biotherapeutics’s most recent deal was a Merger/Acquisition with Flaskworks for . The deal was made on 28-Aug-2020.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Flaskworks | 28-Aug-2020 | Merger/Acquisition | Other Devices and Supplies | ||
| MithraGen | 01-Jan-2008 | Merger/Acquisition | Biotechnology |
Northwest Biotherapeutics ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Northwest Biotherapeutics FAQs
-
When was Northwest Biotherapeutics founded?
Northwest Biotherapeutics was founded in 1996.
-
Where is Northwest Biotherapeutics headquartered?
Northwest Biotherapeutics is headquartered in Bethesda, MD.
-
What is the size of Northwest Biotherapeutics?
Northwest Biotherapeutics has 25 total employees.
-
What industry is Northwest Biotherapeutics in?
Northwest Biotherapeutics’s primary industry is Drug Discovery.
-
Is Northwest Biotherapeutics a private or public company?
Northwest Biotherapeutics is a Public company.
-
What is Northwest Biotherapeutics’s stock symbol?
The ticker symbol for Northwest Biotherapeutics is NWBO.
-
What is the current stock price of Northwest Biotherapeutics?
As of 13-Jun-2025 the stock price of Northwest Biotherapeutics is $0.28.
-
What is the current market cap of Northwest Biotherapeutics?
The current market capitalization of Northwest Biotherapeutics is $400M.
-
What is Northwest Biotherapeutics’s current revenue?
The trailing twelve month revenue for Northwest Biotherapeutics is $1.47M.
-
Who are Northwest Biotherapeutics’s competitors?
Aura Biosciences, Apellis Pharmaceuticals, Oncorus, Advanced Proteome Therapeutics, and Sagimet Biosciences are some of the 55 competitors of Northwest Biotherapeutics.
-
What is Northwest Biotherapeutics’s annual earnings per share (EPS)?
Northwest Biotherapeutics’s EPS for 12 months was -$0.07.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
